The Role of Multiparametric MRI and MRI–targeted Biopsy in the Diagnosis of Radiorecurrent Prostate Cancer: An Analysis from the FORECAST Trial

Alexander Light\textsuperscript{a,b}, Abi Kanthabalan\textsuperscript{c}, Marjorie Otieno\textsuperscript{c}, Menelaos Pavlou\textsuperscript{d}, Rumana Omar\textsuperscript{d}, Sola Adeleke\textsuperscript{e,f}, Francesco Giganti\textsuperscript{g,h}, Chris Brew-Graves\textsuperscript{i}, Norman R. Williams\textsuperscript{c}, Amr Emara\textsuperscript{i}, Athar Haroon\textsuperscript{j,k}, Arash Latifoltojar\textsuperscript{l}, Harbir Sidhu\textsuperscript{g,h}, Alex Freeman\textsuperscript{m}, Clement Orczyk\textsuperscript{c,n}, Ashok Nikapota\textsuperscript{o}, Tim Dudderidge\textsuperscript{p}, Richard G. Hindley\textsuperscript{i}, Jaspal Virdi\textsuperscript{q}, Manit Arya\textsuperscript{b}, Heather Payne\textsuperscript{m}, Anita V. Mitra\textsuperscript{r}, Jamshed Bomanji\textsuperscript{k}, Mathias Winkler\textsuperscript{a,b}, Gail Horan\textsuperscript{s}, Caroline M. Moore\textsuperscript{c,n}, Mark Emberton\textsuperscript{c,n}, Shonit Punwani\textsuperscript{g,h}, Hashim U. Ahmed\textsuperscript{a,b,c,y}, Taimur T. Shah\textsuperscript{a,b,c,s,*}\textsuperscript{1}

\begin{itemize}
\item \textsuperscript{a}Imperial Prostate, Department of Surgery and Cancer, Imperial College London, London, UK; \textsuperscript{b}Imperial Urology, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK; \textsuperscript{c}Division of Surgery & Interventional Science, University College London, London, UK; \textsuperscript{d}Department of Statistical Science, University College London, London, UK; \textsuperscript{e}Department of Oncology, Guy’s and St Thomas’ NHS Foundation Trust, London, UK; \textsuperscript{f}School of Cancer & Pharmaceutical Sciences, King’s College London, London, UK; \textsuperscript{g}Department of Radiology, University College London Hospital NHS Foundation Trust, London, UK; \textsuperscript{h}Division of Medicine, Faculty of Medicine, University College London, London, UK; \textsuperscript{i}Department of Urology, Basingstoke and North Hampshire Hospital, Hampshire Hospitals NHS Foundation Trust, Basingstoke, UK; \textsuperscript{j}Department of Nuclear Medicine, St Bartholomew’s Hospital, Barts Health NHS Trust, London, UK; \textsuperscript{k}Institute of Nuclear Medicine, University College London Hospitals NHS Foundation Trust, London, UK; \textsuperscript{l}Department of Urology, University College London Hospital NHS Foundation Trust, London, UK; \textsuperscript{m}Sussex Cancer Centre, Royal Sussex County Hospital, University Hospitals Sussex NHS Foundation Trust, Brighton, UK; \textsuperscript{n}Department of Urology, University Hospital Southampton NHS Foundation Trust, Southampton, UK; \textsuperscript{o}Department of Urology, The Princess Alexandra Hospital NHS Trust, Harlow, UK; \textsuperscript{p}Department of Oncology, University College London Hospital NHS Foundation Trust, London, UK; \textsuperscript{q}Department of Oncology, Queen Elizabeth Hospital, The Queen Elizabeth Hospital King’s Lynn NHS Foundation Trust, King’s Lynn, UK
\end{itemize}

\begin{table}[h]
\begin{tabular}{|l|l|}
\hline
\textbf{Article info} & \\
\hline
\textbf{Article info} & \\
\hline
\textbf{Article history:} & Accepted September 4, 2023 \\
\hline
\textbf{Associate Editor:} & Maarten Albersen \\
\hline
\end{tabular}
\end{table}

\textbf{Abstract}

\textbf{Background:} The role of multiparametric magnetic resonance imaging (MRI) for detecting recurrent prostate cancer after radiotherapy is unclear.

\textbf{Objective:} To evaluate MRI and MRI-targeted biopsies for detecting intraprostatic cancer recurrence and planning for salvage focal ablation.

\textbf{Design, setting, and participants:} FOcal RECurrent Assessment and Salvage Treatment (FORECAST; NCT01883128) was a prospective cohort diagnostic study that recruited

\begin{itemize}
\item \textsuperscript{1} These authors are joint senior authors.
\item * Corresponding author. Imperial Prostate, Department of Surgery and Cancer, Hammersmith Hospital, 72 Du Cane Road, London W12 0HS, UK. Tel. +447713245739 \\
E-mail address: tshah@imperial.ac.uk (T.T. Shah).
\end{itemize}

\url{https://doi.org/10.1016/j.eururo.2023.09.001}

0302-2838/© 2023 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
1. Introduction

Radiotherapy is the most common prostate cancer treatment for localised disease; over 13 000 with localised disease undergo external beam radiotherapy in the UK annually with overall excellent long-term survival [1,2]. However, approximately 25% with localised disease will biochemically fail within 10 yr, and this subset of patients will have comparatively poorer outcomes [3]. Within 5 yr of biochemical failure, approximately 50% develop metastases and 20 to 30% die from their cancer [4,5]. Specifically, recurrence localised to the prostate affects 10% of radiotherapy patients and is independently predictive of further developing metastases, cancer-specific mortality, and all-cause mortality [6]. Currently, most radio recurrence is managed with watchful waiting or noncurative androgen-deprivation therapy (ADT), a treatment with unpleasant adverse effects and potentially significant metabolic consequences. For biopsy-proven localised recurrences, European guidelines recommend that local salvage...
treatment can be performed for select patients [7]. Some centres offer whole-gland salvage, for example, radical prostatectomy. Although effective, this carries considerable toxicity [8,9]. Salvage focal therapy targeting the recurrent lesion(s) alone as an alternative may offer good cancer control with reduced toxicity [10,11].

Patient selection for salvage focal therapy is particularly important; beyond detecting the overall presence of radiorecurrent cancer within the gland, recurrent tumours require accurate characterisation and mapping within the prostate. The utility of multiparametric magnetic resonance imaging (MRI) and MRI-targeted biopsies here is unclear. Furthermore, after radiotherapy, MRI interpretation is challenging given factors such as glandular atrophy, reactive inflammation, reduced zonal differentiation, diffuse hypo-intense T2 signal, and artefact from brachytherapy seeds if present [12–14]. In addition, unlike in the primary diagnostic setting, there currently exists no robustly validated recommendations for the conduct or reporting of MRI after radiotherapy. An evaluation of the diagnostic performance of MRI with MRI-targeted biopsies is therefore needed, alongside investigating the added value of systematic biopsies, and describing the characteristics of tumours overlooked by MRI. These aims were addressed in a secondary analysis of the FOcal RECurrent Assessment and Salvage Treatment (FORECAST) trial [11].

2. Patients and methods

2.1. Study population

FORECAST was a prospective paired-cohort diagnostic study coupled with an evaluation of adverse events, side effects, and early cancer control following salvage focal ablation (NCT01883128) [11,15]. From 2014 to 2018, 181 patients from six UK centres were enrolled. The inclusion criteria were biochemical failure defined by rising prostate-specific antigen (PSA) levels after external beam radiotherapy or brachytherapy with or without (neo)adjuvant ADT. Biochemical failure was defined by the referring clinician; whilst some oncologists use the Phoenix criteria for this, the study protocol did not insist on a specific threshold [15,16]. Those taking ADT within 6 mo of enrolment, with a PSA doubling time of ≤3 mo, a total PSA value of ≥20 ng/ml, unable to undergo MRI, or who had undergone salvage treatment were excluded. For this analysis, patients were required to have MRI and biopsy data available at the prostate quadrant level.

Gleason grade and PSA before radiotherapy were not exclusion criteria. In FORECAST, patients also underwent MRI with biopsy regardless of N and M staging. Consistent with this, nodal and/or metastatic spread was not an exclusion criterion here. However, a subgroup analysis was performed by repeating analyses in patients with prostate-confined radiorecurrence (N0M0).

2.2. Trial procedures

Following 18F-choline positron emission tomography/computed tomography (PET/CT) and 18F-DCFPyL, prostate MRI was performed using a 1.5 or 3.0 Tesla scanner and a pelvic phased array coil with no endorectal coil. The likelihood of intraprostatic radiorecurrent cancer was reported with a five-point Likert score by one of seven blinded radiologists with at least 5 yr of experience in reporting prostate MRI. The Likert system was used as the Prostate Imaging Reporting and Data System score, which is not validated for this setting, and the Prostate Magnetic Resonance Imaging for Local Recurrence Reporting (PI-RR) score was published only recently [14]. Participants then underwent a cognitive MRI-targeted biopsy for lesions with a Likert score of ≥3, with a recommendation to take four to six cores per target. This was followed in the same session by a transperineal template prostate mapping (TPPM) biopsy, where a biopsy was taken every 5 mm using a brachytherapy grid, in addition to further biopsies to sample the full cranio-caudal length. The Supplementary material describes further details on trial procedures.

2.3. Outcomes

First, the diagnostic accuracy of MRI for radiorecurrence at the patient and prostate quadrant levels was calculated. Second, the pathological characteristics of MRI-detected versus MRI-undetected tumours were compared. At the patient level, PSA, T stage, and NM stage were also compared. Third, an MRI-targeted biopsy alone was compared with three other biopsy strategies involving an MRI-targeted biopsy with additional systematic biopsies of adjacent quadrants. This aimed to investigate the added diagnostic value of perilesional sampling, as has been shown to be important in the primary diagnostic setting, and whether this could be performed in lieu of whole-gland sampling [17].

Figure 1 illustrates how biopsies were performed in FORECAST and the specific strategies tested here. At the patient level, for each strategy, the number of patients with cancers missed was determined, in addition to the number of these patients with cancer that harboured additional tumours in unsampled quadrants. The reference standard for these calculations was whole-gland TPM and MRI-targeted biopsies. As a secondary outcome, the suitability of patients for focal ablative techniques was evaluated based on their biopsy and staging data.

As the precise role of Gleason grading in radiorecurrence has not been established, analyses primarily focused on the detection of cancer of any grade or length. However, the following protocol-described definitions were also used, which are considered definitions of clinically significant disease requiring treatment in the primary setting: (1) grade group ≥3 and/or maximum cancer core length (MCCL) ≥6 mm of any grade (PROMIS definition 1) and (2) grade group ≥2 and/or MCCL ≥4 mm of any grade (PROMIS definition 2) [15,18].

2.4. Statistical analysis

The prostate was divided into quadrants (left/right; anterior/posterior), with a line crossing anterior to the urethral margin marking the anterior/posterior boundary (Fig. 1). Further information on the rules used to allocate biopsy cores to quadrants is detailed in the Supplementary material.

Sensitivity, specificity, positive predictive value, and negative predictive value were calculated for MRI lesion visibility against the reference standard of 5 mm TPM with MRI-targeted biopsies. At the quadrant level, 95% confidence intervals (95% CIs) were derived using cluster bootstrapping with 10 000 resamples. With each patient representing a cluster, this technique was performed to handle correlated quadrant-level data from individual patients. Analyses were performed primarily using MRI visibility thresholds of Likert ≥3 and then adjusted to ≥4. The proportion of patients who had cancer detected and missed at each Likert threshold was also determined.

The characteristics of MRI-detected and MRI-undetected tumours were compared using the Wilcoxon rank sum test for continuous variables (PSA, total biopsy cores, positive biopsy cores, and MCCL). For ordinal variables (grade group, T stage, and NM stage), the chi-square test for trend was used to assess whether these had a linear relationship with MRI visibility.
For a biopsy strategy analysis, only patients with both MRI-targeted and TTPM biopsies were included. If patients had an MRI target in several quadrants, the strategy’s rules were applied to each quadrant. For example, consider a patient with targets in the right posterior and left posterior quadrants; in strategy 2, the patient would undergo MRI-targeted biopsies of both posterior quadrants with systematic biopsies of both anterior quadrants. The proportions of missed cancer and proportions of cancers in unsampled quadrants were determined with...
95% CIs calculated using the modified Wald method [19]. For each of these metrics, Fisher’s exact test was used to make a pairwise comparison between an MRI-targeted biopsy alone (strategy 1) and the best performing strategy among strategies 2–4.

Suitability for focal ablation was assessed for men with localised disease (<T3N0M0) for the following focal techniques: quadrant, bilateral quadrant, left or right hemigland, posterior hemigland, and hockey stick. Bilateral quadrant ablation was indicated for cancer in two nonadjacent quadrants. Hockey stick ablation was indicated for cancer in three quadrants. If cancer was present in all quadrants, whole-gland ablation was indicated. If cancer was present in two nonadjacent quadrants, hockey stick ablation was indicated. If cancer was present in three quadrants, bilaterally quadrant ablation was indicated. If cancer was present in all quadrants, whole-gland ablation was indicated.

Across all cancer definitions (0.95 to 0.98). However, specificity was very poor (0.19 to 0.21). Across the whole cohort, among 144 patients, 91 to 106 (63 to 74%) had cancer diagnosed and enrolment in FORECAST.

3. Results

3.1 Patient characteristics

Figure 2 details the flow chart for patient eligibility, with patient characteristics shown in Table 1. Of 144 eligible patients, 84 (58%) underwent MRI-targeted biopsy in addition to 5 mm TTPM biopsy. The median PSA nadir was 0.30 ng/ml (interquartile range [IQR] 0.10 to 0.52), and the median PSA at trial enrolment was 3.80 ng/ml (IQR 2.40 to 6.17); the median increase of PSA from nadir was 3.50 ng/ml (IQR 2.10 to 6.00). Of the 109 men for whom it was possible to calculate the PSA increase from nadir, 86 (79%) met the Phoenix criteria [16]. In all, 130 patients (90%) previously underwent external beam radiotherapy and 15 (10%) brachytherapy. Of 136 patients with available data, 79 patients (58%) received neoadjuvant ADT and 31/136 (23%) received adjuvant ADT. The median age at enrolment was 71 yr (IQR 67 to 76), and there was a median of 7 yr (IQR 5 to 10) between the points of original diagnosis and enrolment in FORECAST.

3.2 MRI diagnostic accuracy

Following 5 mm TTPM with or without MRI-targeted biopsies, 111/144 (77%) patients had cancer diagnosed. Of 144 patients, 93 (65%) and 108 (75%) had definition 1 and 2 cancers diagnosed, respectively. At the patient level, using the Likert ≥3 threshold, five of all 111 (5%) cases of cancer were undetected by MRI, with 2/93 (2%) definition 1 and 5/108 (5%) definition 2 cancers being undetected. Supplementary Table 1 details the diagnostic accuracy of MRI for each cancer definition at the patient and quadrant levels, and Table 2 details the number of cancers detected and missed by a biopsy at different Likert thresholds. At the patient level, using the Likert ≥3 threshold, sensitivity was very high across all cancer definitions (0.95 to 0.98). However, specificity was very poor (0.19 to 0.21). Across the whole cohort, among 144 patients, 91 to 106 (63 to 74%) had cancer detected and two to five (1 to 3%) had cancer missed at the Likert ≥3 threshold following TTPM with or without MRI-targeted biopsies.

At the quadrant level, of 576 quadrants, 258 (45%) had any cancer, 195 (34%) had definition 1 cancer, and 235 (41%) had definition 2 cancer. Using the Likert ≥3 threshold, 87 of all 258 (34%) cases of cancer were overlooked by MRI, compared with 61/195 (31%) definition 1 cancers, and 79/235 (34%) definition 2 cancers. Sensitivity was 0.66 to 0.69, with specificity 0.52 to 0.54. Across the whole cohort, among 576 quadrants, 134 to 171 quadrants (23 to 30%) had cancer diagnosed and 61 to 87 (11 to 15%) had cancer missed at the Likert ≥3 threshold following TTPM with or without MRI-targeted biopsies.

With the Likert ≥4 threshold, at the patient level, 19 of all 111 (17%) cases of cancer were undetected by MRI, with 14/93 (15%) and 19/108 (18%) definition 1 and 2 cancers undetected, respectively. Sensitivity was 0.82 to 0.85 and specificity improved to 0.63 to 0.82. Across the whole cohort, among 144 patients, 79 to 92 (55 to 64%) had cancer detected and 14 to 19 patients (10 to 13%) had cancer missed at the Likert ≥4 threshold following TTPM with or without MRI-targeted biopsies. With the Likert ≥4 threshold, at the quadrant level, 145 of all 258 (56%) cases of cancer were overlooked by MRI, compared with 102/195 (52%) definition 1 cancers and 131/235 (56%) definition 2 cancers. Sensitivity was poorer (0.44 to 0.48) but specificity very high (0.89 to 0.94). Across the whole cohort, among 576 quadrants, 93 to 113 (16 to 20%) had cancer diagnosed.
3.3. MRI-detected versus MRI-undetected cancers

At the patient level (n = 144), with the Likert ≥3 threshold, no statistically significant difference was observed between patients with MRI-undetected and MRI-detected tumours with respect to PSA, T stage, or NM stage at trial enrolment (Supplementary Table 2).

Table 3 details the comparison of MRI-detected versus MRI-undetected tumours at the quadrant level, using the Likert ≥3 threshold (n = 576). MRI-detected tumours had significantly longer MCCL (median difference 3 mm [7 vs 4 mm]; 95% CI 1 to 4 mm, p < 0.001). In addition, with higher-grade group, a significantly greater proportion of tumours were detected by MRI (chi-square test for trend p = 0.002). Specifically, MRI-detected disease comprised 3/7 (43%) grade group 1 tumours, 24/43 (56%) grade group 2 tumours, 50/80 (63%) grade group 3 tumours, 27/39 (69%) grade group 4 tumours, and 40/49 (82%) grade group 5 tumours. This trend was also observed at the whole-gland level (Supplementary Table 2).

3.4. Biopsy strategies

Of the 84 patients with matched TTPM and MRI-targeted biopsies included for a biopsy analysis, 33 (39%) had one targeted quadrant at the Likert ≥3 threshold, 34 (40%) had two targeted quadrants, 14 (17%) had three targeted quadrants, and three (4%) had four targeted quadrants.

Of 84 patients, any cancer was diagnosed in 73 (87%), whilst 67 (80%) and 73 (87%) had definition 1 and 2 cancers, respectively. Supplementary Table 3 details the performance of MRI-targeted biopsies only (strategy 1) stratified by the Likert score threshold, and Table 4 details the number of missed cancers per biopsy strategy at the patient level.

For cancer of any grade or length, with MRI-targeted biopsies only, 5/73 patients (7%; 95% CI 3 to 15%) would have had their cancer missed. For definition 1 and 2 cancers, respectively, 7/67 (10%; 95% CI 5 to 20%) and 8/73 patients (11%; 95% CI 5 to 20%) would have had cancer missed. Across cancer definitions, with other biopsy strategies, the number of patients with missed cancer ranged from 3 to 8% for strategies that systematically sampled one additional quadrant per target (strategies 2 to 3) to 1 to 3% for strategy 4, which systematically sampled two additional quadrants per target. In a pairwise comparison between MRI-targeted biopsy only and the best performing strategy, strategy 4, there was no statistically significant differences in the proportion of patients with missed cancer, for each cancer definition.

For the 73 patients with biopsy-confirmed cancer, for each biopsy strategy, the number of patients harbouring additional tumours in nonbiopsied quadrants was next calculated (Table 4). Across definitions, MRI-targeted biopsy only resulted in the highest proportion of patients with cancer in unsampled quadrants, affecting 59% of patients (95% CI 47 to 69%) for cancer of any grade or length, 45% (95% CI 33 to 57%) for definition 1 cancer, and 49% (95% CI 38 to 61%) for definition 2 cancer. Sampling one additional quadrant lowered this to 24 to 38% (strategies 2 to 3) to 1 to 3% for strategy 4, which systematically sampled two additional quadrants per target. In a pairwise comparison of MRI-targeted biopsy only and the best performing strategy, strategy 4, there was no statistically significant differences in the proportion of patients with missed cancer, for each cancer definition.
missed at the Likert ≥3 visibility threshold. 77% patients had cancer detected, and 1 to 4% had cancer without MRI-targeted biopsies (Supplementary Table 6).

Across the subgroup, 66 to 24 to 51%, p < 0.0001); and for definition 2 cancer, the difference was 40% (49% vs 10%; 95% CI 26 to 53%, p < 0.0001).

### 3.5. Eligibility for salvage focal ablation

Of 73 patients, 43 (59%; 95% CI 47 to 69%) had biopsy-confirmed localised (≤T3bN0M0) radiorecurrent cancer and were suitable for a form of focal ablation. This included eight (11%) for quadrant ablation, one (1%) for bilateral quadrant ablation, 11 (15%) for left or right hemigland ablation, eight (11%) for posterior hemigland ablation, and 15 (21%) for a hockey stick ablation. Ten (14%) patients would have required whole-gland ablation.

### 3.6. NOM0 subgroup analysis

Analyses were repeated for the 108 men with localised NOM0 radiorecurrent disease, of whom 64 underwent an MRI-targeted biopsy (Supplementary Fig. 1 and Supplementary Table 4). Findings were consistent with our main analysis. At the Likert ≥3 threshold, sensitivity and specificity at the patient level were 0.95 to 0.99 and 0.17 to 0.19, respectively (Supplementary Table 5). Across the subgroup, 66 to 77% patients had cancer detected, and 1 to 4% had cancer missed at the Likert ≥3 threshold following TTPM with or without MRI-targeted biopsies (Supplementary Table 6).

At the quadrant level, sensitivity and specificity were 0.68 to 0.71 and 0.56 to 0.60, respectively (Supplementary Table 5). Of the quadrants, 25 to 32% had cancer detected, and 10 to 15% had cancer missed at the Likert ≥3 threshold following TTPM with or without MRI-targeted biopsies (Supplementary Table 6).

At the quadrant level, with increasing grade group, tumours were more likely to be MRI visible (chi-square test for trend p = 0.006). MRI-visible tumours also had longer MCCL (median difference 3 mm [7 vs 4 mm]; 95% CI 0 to 4 mm, p < 0.001; Supplementary Tables 7 and 8).

Overall, with MRI-targeted biopsy only (strategy 1), 2/56 (4%; 95% CI 0 to 13%) patients had cancer of any grade or length missed, 4/51 (8%; 95% CI 3 to 19%) had definition 1 cancer missed, and 5/56 (9%; 95% CI 3 to 20%) had definition 2 cancer missed (Supplementary Tables 9 and 10). In men with biopsy-confirmed cancer, performing an MRI-targeted biopsy would have missed cancer in other quadrants in 49 to 59%, reducing to 27 to 39% with systematic sampling of one additional quadrant (strategies 2 to 3) and 10 to 13% with systematic sampling of two additional quadrants (strategy 4; Supplementary Table 10). On comparison of strategy 4 with strategy 1, this was a significant reduction for each cancer definition (p < 0.0001 for each definition).

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>MRI undetected (n = 87)</th>
<th>MRI detected (n = 171)</th>
<th>Difference (95% CI)</th>
<th>p value b</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total biopsy cores</td>
<td>10 (8 to 16)</td>
<td>12 (9 to 15)</td>
<td>2 (~2 to 3)</td>
<td>0.2</td>
</tr>
<tr>
<td>Positive biopsy cores</td>
<td>3 (1 to 6)</td>
<td>4 (2 to 7)</td>
<td>1 (0 to 1)</td>
<td>0.004</td>
</tr>
<tr>
<td>Grade group, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>4 (5)</td>
<td>3 (2)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>19 (22)</td>
<td>24 (14)</td>
<td>5</td>
<td>0.002</td>
</tr>
<tr>
<td>3</td>
<td>30 (35)</td>
<td>50 (29)</td>
<td>20</td>
<td>0.002</td>
</tr>
<tr>
<td>4</td>
<td>12 (14)</td>
<td>27 (16)</td>
<td>15</td>
<td>0.002</td>
</tr>
<tr>
<td>5</td>
<td>9 (10)</td>
<td>40 (24)</td>
<td>31</td>
<td>0.002</td>
</tr>
<tr>
<td>Undeterminable/irradiation effect</td>
<td>13 (15)</td>
<td>27 (16)</td>
<td>14</td>
<td>0.002</td>
</tr>
<tr>
<td>MCCL (mm)</td>
<td>4 (2 to 8)</td>
<td>7 (4 to 10)</td>
<td>3 (1 to 4)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Undeterminable</td>
<td>15</td>
<td>2</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CI = confidence interval; IQR = interquartile range; MCCL = maximum cancer core length; MRI = magnetic resonance imaging. This analysis pertains to all 144 men included, equating to 576 prostate quadrants.

a Wilcoxon rank sum test (total biopsy cores, positive biopsy cores, and MCCL); chi-square test for trend (grade group).

b Median (IQR); n (%).
Table 4 – Comparison of biopsy strategies, calculating the number of patients with cancer missed by the strategy and the number of patients with cancer who also harboured tumours in quadrants not sampled by that particular biopsy strategy

<table>
<thead>
<tr>
<th>Cancer definition</th>
<th>Strategy 1</th>
<th>Strategy 2</th>
<th>Strategy 3</th>
<th>Strategy 4</th>
<th>Difference between strategy 1 and best other strategy</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any cancer (n = 73)</td>
<td>5; 7% (1 to 13%)</td>
<td>4; 5% (2 to 14%)</td>
<td>2; 3% (0 to 10%)</td>
<td>2; 3% (0 to 10%)</td>
<td>4% (3 to 11%); 0.4*</td>
<td></td>
</tr>
<tr>
<td>Patients with cancer missed</td>
<td>43; 59% (47 to 69%)</td>
<td>28; 38% (28 to 50%)</td>
<td>20; 27% (18 to 39%)</td>
<td>7; 10% (4 to 19%)</td>
<td>49% (36 to 62%); &lt;0.0001*</td>
<td></td>
</tr>
<tr>
<td>Patients with cancer harbouring additional tumours in unsampled quadrants</td>
<td>30; 45% (33 to 57%)</td>
<td>17; 25% (16 to 37%)</td>
<td>16; 24% (15 to 35%)</td>
<td>5; 7% (3 to 17%)</td>
<td>37% (24 to 51%); &lt;0.0001*</td>
<td></td>
</tr>
<tr>
<td>PROMIS definition 1Grade group ≥ 3 and/or MCCL ≥ 6 mm cancer of any grade (n = 67)</td>
<td>8; 11% (5 to 20%)</td>
<td>6; 8% (4 to 17%)</td>
<td>3; 3% (0 to 10%)</td>
<td>2; 3% (0 to 10%)</td>
<td>8% (0 to 16%); 0.1*</td>
<td></td>
</tr>
<tr>
<td>Patients with cancer missed</td>
<td>36; 49% (38 to 61%)</td>
<td>24; 33% (23 to 44%)</td>
<td>18; 25% (16 to 36%)</td>
<td>7; 10% (4 to 19%)</td>
<td>40% (20 to 53%); &lt;0.0001*</td>
<td></td>
</tr>
<tr>
<td>Patients with cancer harbouring additional tumours in unsampled quadrants</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

4. Discussion

4.1. Summary

Whilst multiparametric MRI has excellent sensitivity for the diagnosis of radiorecurrence at the patient level, sensitivity is modest at the quadrant level, and 31 to 34% of tumours were undetected by MRI. This suggests that although MRI is likely to detect the overall presence of radiorecurrent cancer, it may not accurately localise all lesions in the gland or the extent of these lesions. MRI-undetected tumours, however, were comparatively smaller and of lower grade.

Given the modest sensitivity of MRI at the quadrant level, whether an MRI-targeted biopsy was sufficient to detect radiorecurrence without additional systematic biopsies was next tested. At the patient level, if only MRI-targeted biopsies were performed, this would have missed disease in 7 to 11% of patients with radiorecurrent cancer. Additional sampling of the other ipsilateral quadrant and contralateral posterior quadrant (strategy 4) reduced this to 1 to 3%. An MRI-targeted biopsy therefore detected the overall presence of radiorecurrent cancer in the majority and is possibly improved further with perilesional sampling.

MRI-targeted biopsies alone, however, were not sufficient for localising all cancerous lesions within the gland. Of patients with radiorecurrent cancer, as many as 45 to 59% would have harboured cancer in unsampled quadrants if only an MRI-targeted biopsy was performed. With strategy 4, this proportion reduced, but only to 7 to 10%, which may still represent an unacceptable miss rate in the context of the aggressive cancer phenotypes observed in radiorecurrent disease [4,5]. Given this, systematic sampling of all quadrants in addition to an MRI-targeted biopsy is recommended to capture MRI-undetected disease for accurate prostate mapping. This would be important for planning salvage focal ablation such that any MRI-undetected cancers are not missed inappropriately during treatment.

4.2. Implications for practice

With the emerging use of salvage focal treatments, it is vital not only to exclude metastases, but also to identify, map, and characterise any intraprostatic disease [20]. Relevant studies are scarce and heterogeneous in design and quality. Our findings, however, agree with other groups that MRI has good sensitivity for detecting radiorecurrence at the patient level, but poorer sensitivity at the level of prostate subdivisions [21–26]. At the patient level, if the primary aim is to detect the overall presence of recurrent cancer, then our work demonstrates that MRI-targeted biopsies with perilesional sampling will identify the majority of patients with recurrence, in keeping with data from the primary diagnostic setting [17,27,28]. MRI-undetected disease here was smaller and of lower grade, also consistent with the findings from primary diagnostic MRI [29,30]. However, although
low-volume, clinically insignificant disease detected on systematic biopsies can often be left untreated in the primary setting, whether the same can be done with equivalent tumours in the radiorecurrent setting is presently unknown. If focal ablation is to be planned, performing MRI-targeted biopsies alone will potentially miss cancer elsewhere in the prostate in three of five patients. This finding aligns with those of a recent study of salvage radical prostatectomy whole-mount histology, where 22/41 (54%) prostates were found to have at least two cancer foci [31]. Thus, the addition of systematic sampling of the whole prostate seems necessary so that any and all MRI-undetected lesions are captured and can be considered for subsequent ablation.

Our group has previously proposed that eligible cancers should be unifocal or unilateral, or bilateral/bifocal with at least one neurovascular bundle spared, or bilateral/multifocal with one dominant index lesion, and secondary lesions having no more than 3 mm of grade group 1 disease [20]. Beyond detecting the presence versus absence of radiorecurrent cancer, accurate prostate mapping is therefore crucial to distinguish treatment candidates versus those who should receive whole-gland or other management strategies. Toxicity is also higher following whole-gland versus focal treatments, whether extirpative or ablative [32,33]. Salvage radical prostatectomy can be particularly morbid, associated with erectile dysfunction in nearly 100%, urinary incontinence in nearly 80%, and rectal injury in nearly 10% [8,9].

Irrespective of toxicity, however, the most important reason underpinning a well-planned focal ablation is the oncological outcome. It is established that patients with biochemical failure after radiotherapy have poor outcomes [6,34,35]. The 5-yr incidence of distant metastases and that of cancer-specific death after biochemical failure are approximately 50% and 20 to 30%, respectively [4,5]. Salvage radical prostatectomy can be particularly morbid, associated with erectile dysfunction in nearly 100%, urinary incontinence in nearly 80%, and rectal injury in nearly 10% [8,9].

The FORECAST trial was a prospective, multicentre, paired-cohort study representing level 1 evidence for diagnostic test validation. This analysis, however, is subject to several limitations. One encompasses quadrant-level analyses, where data points are inherently nonindependent. However, we mitigated against this using cluster bootstrapping at the individual patient level.

Second, 84 patients underwent an MRI-targeted biopsy despite more men having Likert scores of 3 to 5. The reasons for omission of a targeted biopsy were not collected. However, as a TTPM biopsy was performed in the same session, it is likely that an additional targeted biopsy was omitted if a target lesion had already been sampled systematically. The 84 men who underwent an MRI-targeted biopsy had a significantly higher increase in PSA from nadir than those who did not (median difference 1.6 ng/ml [4.4 vs 2.8 ng/ml], p = 0.043). Higher Likert scores (p < 0.001) and higher T stages were also observed in this group (p = 0.046; Supplementary Table 11). No statistically significant difference was observed for other variables such as PSA at trial enrolment and NM stage.

Next, with a median of 7 yr between diagnosis and trial enrolment, our cohort is less representative of modern radiotherapy cohorts. At the initial diagnosis, participants would likely have received a systematic transrectal ultrasound (TRUS)-guided biopsy only, which may have affected the management of the patient [18,38]. On a related note, 27% also had Gleason ≤6 disease at the initial diagnosis. This may represent the sampling limitations of a TRUS biopsy, but regardless, most patients with Gleason ≤6 disease would now be offered active surveillance [7,39]. In addition, a 1.5 Tesla scanner provides reduced signal-to-noise ratio and spatial resolution compared with modern 3.0 Tesla scanners. However, at least in the primary diagnostic setting, it is not clear whether this technical improvement translates to improved outcomes [40]. Furthermore, there is currently no evidence to suggest that magnet strength improves diagnostics in the radiorecurrent setting. Last, staging was done with bone scan and 18F-choline PET/CT, the standard during study recruitment. Prostate-specific membrane antigen (PSMA) PET/CT may better identify occult intraprostatic and extraprostatic recurrences and alter management options [41].

4.4. Further directions

This work would benefit from supplementary analyses using data not collected in FORECAST. For example, studying biopsy complications and post-biopsy functional outcomes relative to the biopsy route, number of cores taken, and quadrants sampled would contribute to the discussion of the optimal biopsy strategy. It is known that a TTPM biopsy with 5 mm sampling, at least in the primary diagnostic setting, frequently mandates a general anaesthetic and is associated with acute urinary retention in approximately one-quarter, as well as deterioration in erectile and sexual function [42]. The functional impact of previous interventions for benign prostatic obstruction, for example, transurethral resection of the prostate, is also not known. The toxicity of biopsy strategies is an important consideration in this population of older men (here, a median age of 71 yr with a median of 7 yr from completing radiotherapy) who have already sustained toxicity from radiotherapy with or without ADT.
Another important analysis is a comparison of location of the primary lesion(s) versus radiorecurrent lesion(s). Radiological and pathological data regarding the site of the original index tumour were not collected, and many cases would have been diagnosed without accurate localisation data because of the pre-MRI diagnostic pathway employed at the time. Nonetheless, others have shown that radiorecurrent disease usually develops at the site of the original index tumour [43,44]. The value of biopsying the index tumour site irrespective of imaging findings should therefore be considered in future work.

Third, to compare a biopsy after radiotherapy versus the primary setting, it would also be useful to identify the rate of core fragmentation and how this varies between prostate zones. Furthermore, collecting data on the presence of other pathologies, such as prostatic intraepithelial neoplasia or inflammation, would improve the understanding of how these correlate with MRI findings. This is especially important considering the high rate of false positive MRI examinations associated with its low specificity.

Further research is also warranted in optimising image interpretation. Robust, multicentre prospective validation of the recently published PI-RR score will be important and could optimise MRI use [14]. There is also growing observational evidence that 68Ga-PSMA-11 PET/CT has high sensitivity for the detection of radiorecurrent intraprostatic cancer and could therefore be used not only to rule out metastases, but also to identify candidates for salvage focal therapies, as has also been suggested in the primary treatment setting [45–48]. This warrants robust evaluation of the diagnostic accuracy of PSMA PET/CT in isolation and combined with MRI alongside the evaluation of cost effectiveness for a healthcare system.

5. Conclusions

For patients with recurrent prostate cancer after radiotherapy, MRI, and MRI-targeted biopsy, with or without perilesional sampling, will diagnose cancer in the majority where present. MRI-undetected cancers, defined as Likert scores of 1 to 2, were found to be smaller and of lower grade. However, if salvage focal ablation is planned, an MRI-targeted biopsy alone is insufficient for prostate mapping; approximately three of five patients with recurrent cancer found on an MRI-targeted biopsy alone harboured further tumours in unsampled quadrants. Systematic sampling of the whole gland should be considered in addition to an MRI-targeted biopsy to capture both MRI-detected and MRI-undetected disease.

Author contributions: Taimur T. Shah had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Light, Ahmed, Shah.
Analysis and interpretation of data: Light, Ahmed, Shah.
Drafting of the manuscript: Light, Ahmed, Shah.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Light.
Administrative, technical, or material support: Light, Shah.
Other: None.

Financial disclosures: Taimur T. Shah certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Alexander Light receives funding from the UK National Institute of Health Research (NIHR) and Imperial Health Charity. Francesco Giganti is a recipient of the 2020 Young Investigator Award (20YOUN15) funded by the Prostate Cancer Foundation / CRIS Cancer Foundation; and receives consulting fees from Lucida Medical Ltd. Caroline M. Moore is funded by the NIHR Research Professorship; receives funding from the European Association of Urology Research Foundation, the UK Medical Research Council, Cancer Research UK, Prostate Cancer UK, Movember, and the Cancer Vaccine Institute; and has received advisory board fees from Genomic Health. Mark Emberton receives funding from NIHR-4i, the UK Medical Research Council, Cancer Research UK, the Jon Moulton Charitable Foundation, Sonablate, Tred Medical, the Cancer Vaccine Institute, and Sophiris Biocorp; and is a consultant and/or trainer and proctor for Sonotherm, Angiodynamics, and Exact Imaging. Shonit Punwani receives sessional funding from UCLH Biomedical Research Centre, and funding from Prostate Cancer UK, the UK Medical Research Council, and Cancer Research UK. Hashim U. Ahmed receives infrastructure support from the NIHR Imperial Biomedical Research Centre and Imperial College Experimental Cancer Medicine Centre; receives core funding from the UK NIHR Imperial Biomedical Research Centre (BRC), the Wellcome Trust, the UK NIHR, the UK Medical Research Council, Cancer Research UK, Prostate Cancer UK, The Urology Foundation, the British Medical Association Foundation, Imperial Health Charity, Sonablate, Tred Medical, and Sophiris Biocorp; has received travel allowance from Sonablate; was a paid consultant for Sophiris Biocorp and Sonablate; and is a proctor for Resixim treatment and cryotherapy for Boston Scientific. Taimur T. Shah receives infrastructure support from the NIHR Imperial BRC and Imperial College Experimental Cancer Medicine Centre; receives research funding from The Urology Foundation, Prostate Cancer UK, and Promaxo Inc; and receives consultancy fees and conference attendance support from Janssen. The remaining authors have nothing to disclose.

Funding/Support and role of the sponsor: The FORECAST study was funded by the Pelican Cancer Foundation, the US National Institutes of Health, and the UK Medical Research Council (NCT01883128). The sponsors played no direct role in the study or this analysis.

Ethics statement: UK Ethics Committee approval was received for the FORECAST trial under reference 13/LO/1401.

Peer Review Summary and Supplementary data

Peer Review Summary and Supplementary data to this article can be found online at https://doi.org/10.1016/j.eururo.2023.09.001.


References


